Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT03745989 Completed - Solid Tumors Clinical Trials

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Start date: February 22, 2019
Phase: Phase 1
Study type: Interventional

This is a multicenter, worldwide, open-label study of MK-8353 in combination with selumetinib in participants with histologically or cytologically confirmed diagnosis of advanced solid tumor. This study will evaluate the safety, tolerability, and exploratory efficacy of MK-8353 in combination with selumetinib.

NCT ID: NCT03745378 Completed - Myelofibrosis Clinical Trials

Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)

MPN-K
Start date: May 15, 2018
Phase:
Study type: Observational

The incidence of secondary cancer (SC) in patients with myeloproliferative neoplasms (MPN) is high and comparable to that of thrombosis. However, the identification of patient subgroups that might be at increased susceptibility of developing SC has not been systematically addressed. This international case-control study (MPN-K) is aimed to elucidate the prognostic role of JAK2V617F mutation in predicting the occurrence of SC in patients with classical MPN, polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF)

NCT ID: NCT03744676 Completed - Lymphoma Clinical Trials

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Start date: November 29, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter, Phase 2 study to determine the safety, PK, and efficacy of lisocabtagene maraleucel (JCAR017) in subjects who have relapsed from, or are refractory to, two lines of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) in the outpatient setting. Subjects will receive treatment with JCAR017 and will be followed for up to 2 years.

NCT ID: NCT03744403 Completed - Clinical trials for Advanced Solid Tumors

A Study of CS1001 in Subjects With Advanced Solid Tumors

Start date: December 4, 2018
Phase: Phase 1
Study type: Interventional

This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.

NCT ID: NCT03738787 Completed - Clinical trials for Postoperative Complications

Treatment of the Pancreatic Stump With Neoprene®-Based Glue After High-risk Pancreatoduodenectomy

Start date: January 1, 2015
Phase: Phase 2
Study type: Interventional

The study evaluates the safety and efficacy of Neoprene-based glue in the management of pancreatic stump after pancreatoduodenectomy (PD) in patients at high risk for pancreatic fistula and early neoplastic recurrence, compared with a population of patients at conventional risk.

NCT ID: NCT03736850 Completed - Clinical trials for Locally Advanced or Metastatic Solid Tumors

Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Start date: October 19, 2018
Phase: Phase 1
Study type: Interventional

This is a multicenter, open label, sequential-cohort, dose escalation & expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006 and to establish the Maximum Tolerated Dose (MTD), if any, Recommended Phase II Doses (RP2Ds) and regimen of CS3006. The study is composed of two parts: Part 1 for dose escalation and Part 2 for dose expansion.

NCT ID: NCT03736473 Completed - Clinical trials for Advanced Solid Malignancies

A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients

Start date: November 7, 2018
Phase: Phase 1
Study type: Interventional

This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of MEDI9447 in Japanese patients with advanced solid malignancies.This study consists of 2 cohorts. Cohort 1 (dose level 1) and Cohort 2 (dose level 2). At least 3 or up to 6 evaluable Japanese patients with advanced solid malignancies will be enrolled in each cohort.

NCT ID: NCT03733587 Completed - Solid Tumor Clinical Trials

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Start date: October 17, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1b study to explore the safety and efficacy of GX-I7 in combination with CPA in patients with metastatic or recurrent solid tumors.

NCT ID: NCT03731819 Completed - Pancreas Cyst Clinical Trials

Establishment of Abbreviated Pancreatobiliary MRI Protocol

Start date: November 5, 2018
Phase: N/A
Study type: Interventional

This study aims to establish abbreviated PB MRI protocol for patients on regular imaging follow-up for pancreas cystic neoplasm.

NCT ID: NCT03730337 Completed - Clinical trials for Advanced or Metastatic Solid Tumors

Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Start date: October 17, 2018
Phase: Phase 1
Study type: Interventional

To evaluate the tolerability and safety of ONO-7475 monotherapy and combinations with ONO-4538 in patients with advanced or metastatic solid tumors